>>> READY TO SHIP PRODUCT
Human iPSC-derived retinal organoids (unaffected, day 150), media, plate and pipettes kit
Human iPSC-derived retinal organoids (unaffected, day 150), media, plate, and pipettes kit for disease modeling, retinal toxicity assessment and drug discovery.
- Derived from human iPSCs
- At day 150, the organoids contain major retinal cell types organized in a laminated manner
- Contain all major retinal cell types, including rods, cones, bipolar, horizontal, amacrine, Müller glia, and ganglion cells
- Stratified, cell layers allow drug permeation
- Suitable for early toxicology workflows, developmental retina research, and drug discovery
Kit components
- 10 retinal organoids per 5 ml microfuge tube
- Optimized cell culture medium
- 96 well plates
- Pasteur pipettes
Our minimum order quantity is 20 organoids to ensure reliable logistics when shipping live cells. Standard unit sizes will be available in kits of 20, 50, and 100 organoids, with custom quantities above 100 provided upon request and for screening purposes. Please contact us to discuss your specific requirements and to receive a quote.
The quantities of the kit components are adjusted according to the number of organoids included in your order.
Contact us at operations@axolbio.com.
Specifications
Number of organoids 10 / vial
Donor male, 68-year-old
Genetics healthy control
Description
iPSC‑derived retinal organoids provide an early‑stage human model for investigating the foundational mechanisms of retinal development and enabling downstream discovery in ophthalmology.
- Maturation potential: contain major retinal cell types organized in a laminated manner
- Identity: express early neuroectodermal and eye‑field markers consistent with initial stages of human retinogenesis
- Research applications: used for studies assessing early retinal fate decisions, developmental transitions, early sensitivity to toxicological stressors, and longitudinal disease‑modelling workflows spanning early to late retinal maturation
Top Resources
Additional Information
Retinal organoids are fully characterised and monitored through the analysis of biomarkers specific for each cell type. For example, for cone photoreceptors, we monitor the expression of OPNSW, OPNMW, OPNLW, ARR3, RXRG; for rod photoreceptors we use RHO and NRL and for retinal ganglion cells we follow MATH5 (ATOH7) and BRN3 (POU4F2). Our organoids are scientifically validated to carry out advanced in vitro assays for many applications.
Depending on the cell type of interest, the organoids can be used at different stages of development
- Retinal ganglion cells are more abundant at day 60
- At day 150 the organoids contain major retinal cell types organized in a laminated manner
- Bipolar cells, cone and rod photoreceptors being more prevalent from day 180
Phenotypic characterization: expression of retinal organoid markers
iPSC-derived retinal organoids contain the major retinal cell types organized in a laminar structure, as shown by the expression of Recoverin (photoreceptors), Rhodopsin (rods), Opsin LW/MW and SW (cones), PKC-α (bipolar cells), AP-2α (amacrine cells), SNCG (ganglion cells), CRALBP (Müller glial cells), and PROX1 (horizontal cells).
Retinal organoids respond to compounds known to induce retinal toxicity in a dose-response manner
Assay overview
Drug treatment effect on retinal cell viability
Dose-response curve demonstrating the dose-dependent effect of known cytotoxic drug to the retina, on retinal organoids.
(A) Organoid health was monitored under the brightfield microscope which showed darker organoids with rougher edges following Thioridazine drug treatment. (B) Cell viability was measured as the percentage of ATP released in treated organoids relative to untreated organoids across increasing drug concentrations. The datapoints represent the average from two experimental repeats(n=2 independent experiments) conducted with 5 biological replicates per dose (n=5 organoids per dose). Day 230 organoids were treated for 24 or 72 hours with the indicated range of compounds concentrations.
- Gene therapy vector assessment using retinal organoids
- Disease modelling with advanced retinal organoid systems
- Investigational drug safety and efficacy
Guided by over a decade of expertise, we ensure confidence in the quality of our iPSC-derived cells with rigorous QC. All cells come with a full Certificate of Analysis to ensure ethical and biological conformity for your peace of mind.
Axol has obtained all relevant licenses for commercial use.
Patient samples used to create these organoids have been ethically sourced and consented for research and commercial use. All cells come with a full Certificate of Analysis and are officially certified by HPSCreg®, to ensure ethical and biological conformity for your peace of mind.
- Li et al., 2025 (Cell Death & Disease) – Applied human iPSC‑derived retinal organoids to investigate molecular mechanisms underlying retinal degeneration, demonstrating the utility of 3D organoid systems for modelling disease‑relevant pathways.
https://www.nature.com/articles/s41419-025-07420-7 - Nakayama et al., 2024 (Journal of Cellular and Molecular Medicine) – Used retinal organoids to examine photoreceptor development and stress‑related responses, supporting their use as reproducible in vitro platforms for mechanistic and drug‑response studies.
https://onlinelibrary.wiley.com/doi/full/10.1111/jcmm.17670 - McClements et al., 2022 (Newcells Biotech) – Characterised AAV vector tropism in photoreceptor‑like cells within human iPSC‑derived retinal organoids, highlighting the relevance of organoid systems for evaluating gene‑therapy vector delivery and performance.
https://newcellsbiotech.co.uk/wp-content/uploads/2022/10/McClements_2022_AAV-tropism-in-retinal-organoids.pdf
- Retinal organoid media, 500 ml